Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
Xiuning LiFrederico Omar Gleber-NettoM Laura RubinYun QingRobyn R DuMerrill KiesGeorge BlumenscheinCharles LuFaye M JohnsonDiana BellJeff LewisJianhua ZhangLei FengKaye WilsonKathrina Marcelo-LewisJing WangLawrence GinsbergMaura L GillisonJiun-Kae Jack LeeFunda Meric-BernstamGordon B MillsWilliam Nassib William JuniorJeffrey N MyersCurtis R PickeringPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The addition of erlotinib to platinum-taxane chemotherapy was well-tolerated but did not induce higher rates of MPR or PFS or OS survival benefit. Patients who received chemotherapy with erlotinib and achieved major pathological responses had excellent clinical outcome.